---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-054774"
form_type: "8-K"
ticker: "RYTM"
cik: "0001649904"
company_name: "RHYTHM PHARMACEUTICALS, INC."
filed_at: "2023-05-02T23:59:59+00:00"
generated_at: "2026-06-16T03:37:50.507479+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rhythm Pharma Q1 revenue $11.5M, net loss $52.2M; BBS prescriptions over 300 since launch

## Summary
- Net product revenue $11.5M in Q1 2023 vs $1.5M YoY; net loss $52.2M ($0.92/sh) vs $52.8M ($1.05/sh).
- Over 300 new BBS prescriptions for IMCIVREE since June 2022 FDA approval; >100 written in Q1 2023.
- First patients dosed in pivotal Phase 3 hypothalamic obesity trial; enrollment completion expected Q1 2024.
- Cash position $294.6M at March 31, 2023, down from $333.3M; FY 2023 Non-GAAP OpEx guidance $200-220M.
- Launched IMCIVREE in Germany for BBS with federal reimbursement on April 24, 2023.

## SEC filing metadata
- accession: 0001104659-23-054774
- form_type: 8-K
- ticker: RYTM
- cik: 0001649904
- company_name: RHYTHM PHARMACEUTICALS, INC.
- filed_at: 2023-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649904/000110465923054774/0001104659-23-054774-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649904/000110465923054774/tm2314243d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-054774
- JSON: https://secwatch.observer/filing/0001104659-23-054774.json
- Plain text: https://secwatch.observer/filing/0001104659-23-054774.txt

## Key facts
- Earnings Releases
  RHYTHM PHARMACEUTICALS, INC. reported first quarter ended March 31, 2023 results: revenue $11.5 million.
  - Period: first quarter ended March 31, 2023
  - Revenue: $11.5 million
  - Result: reported results
  source text: Net product revenues relating to global sales of IMCIVREE were $11.5 million for the first quarter of 2023, as compared to $1.5 million for the first quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649904/000110465923054774/0001104659-23-054774-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.